Overview of Andorex

Quick Facts

Property	Description
Active Ingredients	Benzydamine Hydrochloride, Chlorhexidine Gluconate
Form	Oromucosal Spray or Solution
Pharmacological Class	Topical Anti-inflammatory, Local Analgesic, and Antiseptic
Common Use	Symptomatic treatment for oral and pharyngeal irritation
Origin	Synthetic chemical compound combination

What Type of Medicine is Andorex? (Identity, Class, and Form)

Andorex is primarily defined as a fixed-dose combination drug engineered for topical application within the oropharyngeal region, utilizing the oromucosal route of administration. As a pharmaceutical product, it is classified across the therapeutic groups of Topical Anti-inflammatories, Local Analgesics, and Broad-spectrum Antimicrobials, a combination that is clinically recognized for its effectiveness in addressing both inflammation and microbial presence. This dual classification means the medicine targets multiple facets of oropharyngeal pathology. The standard dosage form is a liquid preparation supplied as an Oromucosal Spray or Solution, designed for efficient coverage of the affected oral mucosal surfaces.

Composition: Benzydamine and Chlorhexidine Gluconate

The efficacy of Andorex is derived from its two synthetic chemical compounds and active ingredients: Benzydamine Hydrochloride and Chlorhexidine Gluconate. Benzydamine functions as an NSAID Analogue, delivering an anti-inflammatory action and a distinct analgesic effect through membrane stabilization. Chlorhexidine, conversely, is a potent antiseptic and disinfectant agent. This fixed composition is prepared in an aqueous-alcoholic solution base, optimizing the delivery of both components for local therapy. This specific combination is a key differentiating factor from numerous single-ingredient oral treatments.

General Purpose of the Dual-Action Formula

The general purpose of this dual-action formula is to provide comprehensive symptomatic treatment by concurrently mitigating pain and addressing microbial contributors to irritation in the mouth and throat. By combining the anti-inflammatory action of Benzydamine with the antimicrobial action of Chlorhexidine, Andorex targets two critical factors in oropharyngeal pathology. This approach facilitates the relief of soreness and discomfort associated with various oropharyngeal conditions by simultaneously reducing inflammation and lowering the microbial load in the oral cavity.

Regulatory References

Chlorhexidine on WHO Essential Medicines List

What side effects are possible with Andorex?

Possible Side Effects and Safety Information

The safety profile for the combination product Andorex (Benzydamine/Chlorhexidine) is based on the classification of adverse reactions documented in official regulatory labeling. These effects are generally local and categorized by frequency and the body system affected.

Documented Adverse Reactions

The most commonly documented local adverse reactions are classified as uncommon and involve transient sensations at the application site. These include numbness (hypoesthesia) and a temporary stinging or burning sensation in the mouth or throat. Other non-serious effects include disturbance of taste and potential for staining of the teeth, tongue, or dental fillings, which is primarily associated with prolonged use of the Chlorhexidine component.

Adverse reactions are formally grouped by regulatory agencies under system-organ classes, including Gastrointestinal Disorders, Nervous System Disorders, and Immune System Disorders.

Serious Safety Considerations

Official regulatory documents classify the possibility of rare, but clinically significant, adverse reactions. The most serious concern involves anaphylactic reaction, a severe, potentially life-threatening form of immediate hypersensitivity linked to Chlorhexidine. Other serious reactions classified as very rare include severe allergic responses such as laryngospasm or bronchospasm.

Safety Constraints and Special Populations

Regulatory safety information specifies that use is not advised during pregnancy or lactation due to a lack of definitive clinical data on topical exposure and the known risks associated with systemic NSAID analogues (Benzydamine). A safety restriction also advises caution for individuals with known hypersensitivity to aspirin or other NSAIDs.

These official safety statements structure the risk profile by distinguishing between expected, self-limiting local effects and rare, yet critical, systemic immune responses.

Overdose and Emergency Response

The official regulatory profile for Andorex overdose focuses on the risks associated with the accidental ingestion of quantities significantly exceeding the recommended topical dose. Systemic effects are primarily related to the absorption of high doses of the Benzydamine component.

Documented Overdose Manifestations

Accidental ingestion, often defined as absorbing over 300 mg of Benzydamine, may result in manifestations impacting the Central Nervous System (CNS) and the Gastrointestinal (GI) system. Documented CNS symptoms include hallucinations, anxiety, agitation, dizziness, somnolence, and, in severe cases, convulsions. Gastrointestinal symptoms typically include nausea, vomiting, abdominal pain, and irritation of the esophagus.

Emergency Action and Required Treatment

Seek immediate medical attention or contact a Poison Control Center (PCC) immediately if accidental overdose or the swallowing of large volumes is suspected. The regulatory information states that no specific antidote is known for systemic Benzydamine toxicity. Therefore, treatment is strictly symptomatic and supportive. Supportive measures, such as gastric decontamination, including the administration of activated charcoal, may be indicated based on professional medical guidance.

Population-Specific Risk

A specific risk is noted for small children who accidentally ingest the solution: they may exhibit signs of alcohol intoxication due to the excipient base, a situation that also warrants immediate medical evaluation.

Therapeutic Uses of Andorex

What Andorex Treats: Main Uses and Benefits

Andorex is commonly used across domains where supportive symptom management is appropriate for inflammatory and irritative conditions of the mouth and throat. The therapeutic relevance of the main active ingredient is commonly associated with easing pain and swelling related to sores, oral inflammation, and painful swallowing. This combination formulation is considered relevant in contexts marked by increased discomfort or functional stress across several key symptom clusters.

Relief of Acute Throat Inflammation and Pain

The medicine is commonly used across conditions presenting with acute or disruptive episodes, such as pharyngitis (sore throat) and tonsillitis. It is applied in addressing symptom clusters that may become intense or disruptive, specifically soreness, redness, and pain on swallowing, and may contribute to easing the overall symptom load during periods when symptoms are more noticeable. The conditions in which the medicine is commonly applied include sore throat, gingivitis, stomatitis, and pharyngitis.

“The medication's primary therapeutic aim is to assist with easing functional symptoms during acute episodes.”

Management of Oral Irritation and Post-Procedural Discomfort

Andorex is considered relevant in conditions involving inflammatory or irritative processes affecting the oral mucosa, including stomatitis and gingivitis. It is applied in scenarios where short-term symptomatic assistance is appropriate, and may support general well-being during symptomatic phases. The product is also applied in clinical settings following minor dental procedures like extractions or for localized irritation caused by physical elements like orthodontic appliances. In these situations, it provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Acute Discomfort
Primary Therapeutic Area: Symptomatic easing of pain, inflammation, and soreness.
Key Benefit: Contributes to improved comfort during periods of heightened irritation.
Typical Context: Conditions marked by acute inflammation and post-traumatic oral irritation.

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Andorex

Based on authoritative regulatory documents, the use of Andorex (Benzydamine and Chlorhexidine) is strictly defined by specific population criteria and contraindications. This section outlines the official eligibility and non-eligibility rules.

Contraindications (Must Not Be Used)

The medicine is contraindicated and must not be used by the following groups:

Hypersensitivity: Individuals with a known allergy to the active ingredients Benzydamine, Chlorhexidine, or any other excipients in the formulation.
Pregnancy: Women who are pregnant.
Lactation: Women who are breastfeeding.

Eligibility and Restrictions

Population Group	Regulatory Status
Children under 12 years	Use not recommended due to insufficient clinical study data. Some sources contraindicate use under 6 years.
Adults (18+ years)	Generally eligible, provided no contraindications exist.
Severe Liver Disorder	Requires special caution due to Benzydamine's metabolism in the liver.
Renal Disorder	Requires special caution due to elimination via the kidneys.

Eligibility is primarily constrained by absolute prohibitions for known allergies and for pregnant or breastfeeding women. Use is conditional or not recommended for specific age groups and patients with compromised organ function.

What should I know about interactions with other medicines?

The official regulatory interaction profile for this topical medicine is defined primarily by its local chemical properties rather than systemic drug-drug interactions. Regulatory documentation confirms that no systemic metabolic or pharmacokinetic interactions have been established for the Benzydamine component, a status attributed to its very limited systemic absorption when used topically.

Topical and Chemical Incompatibilities

The key regulatory focus is on the Chlorhexidine component, which is subject to Topical Chemical Incompatibility. This means the product's antimicrobial action can be reduced or entirely inactivated by contact with anionic compounds, such as those commonly found in conventional toothpastes, mouthwashes, or soaps. Certain anionic polyelectrolytes (e.g., Sodium alginate) are also documented to reduce activity.

To prevent this loss of activity, official guidelines impose strict Administration Timing Restrictions. Individuals must thoroughly rinse their mouth with water between brushing their teeth with an anionic dentifrice and applying the product. This separation is mandatory to prevent a local chemical interaction that compromises efficacy.

Furthermore, the Chlorhexidine salts may chemically precipitate if diluted or mixed with certain substances. This includes the metallic cations found in hard waters (such as Ca^+2 and Mg^+2), or with solutions containing high concentrations of benzoates, bicarbonates, or phosphates. Conversely, the product is chemically compatible with, and shows pharmacodynamic synergism with, specific other cationic agents like Cetrimide.

Mechanism of Action

Modulating Local Pain Signaling via Ion Channel Blockade

The active component, Benzydamine, engages mechanisms resulting in local neural inexcitability by directly engaging with voltage-gated Na^+ channels on sensory nerve membranes. This interaction rapidly blocks the flow of Na^+ ions, fundamentally inhibiting the propagation of nerve impulses. This mechanistic domain influences the rate of nerve signal propagation, which facilitates a localized reduction in impulse transmission.

Dual Action on Anti-inflammatory Mediators

Benzydamine's anti-inflammatory mechanism involves pathways distinct from primary COX-inhibition. It includes the inhibition of pro-inflammatory mediators, such as TNF-alpha and IL-1beta, and stabilization of cell membranes. This mechanistic cascade modifies the early molecular steps of the inflammatory response, which results in limitation of excessive mediator activity and affects tissue fluid dynamics and cell migration.

Antiseptic Effect through Microbial Cell Disruption

Chlorhexidine exerts its effect via a physical-chemical mechanism as a cationic surfactant. It targets the negatively charged components of microbial cell walls and membranes, initiating a sequence of structural disruption and destabilization. This mechanism leads to the reduction of microbial cell viability, which influences the microbial load within the local environment.

Dosage and Administration Information

How Andorex is Used: Official Administration Guidelines

Andorex, a combination of Benzydamine Hydrochloride and Chlorhexidine Gluconate, is intended exclusively for local oromucosal administration as a rinse, gargle, or spray, and must not be swallowed. The instructions below reflect high-level usage patterns.

Standard Dosing and Frequency

The medicine is used on an as-needed basis with specific limitations on dose size and frequency. For adult use, the dose is standardized to 15 mL for the rinse/gargle solution or 5 –10 actuations (sprays) per application. Doses may be repeated, but a minimum interval of 1.5 to 3 hours must be observed between applications.

Procedural Conditions

Procedural Element	Official Instruction
Preparation	The solution is generally used undiluted, but may be diluted with water if stinging occurs.
Post-use Handling	The solution must be expelled (spit out) and not ingested after use.
Duration Limit	Continuous, uninterrupted use must not exceed 7 days.
Missed Dose	A forgotten dose should be skipped to maintain the schedule; do not double the next dose.

Population-Specific Rules

Use of Andorex is generally not recommended for children under 12 years due to insufficient data. For children over 12 years, the dose may range from 5 to 15 mL of the solution every 1.5 –3 hours. No dose adjustment is typically specified for older adults.

Recent Clinical Evidence

Research evidence / Overview of studies for Andorex

The research evidence for the combination of Benzydamine and Chlorhexidine was evaluated in short-term, randomized controlled trials (RCTs) and systematic reviews, which explored the medicine’s supportive role in addressing symptoms associated with oral and pharyngeal irritation, as explored in research. This evidence base is designed to provide context for what has been studied and what remains an area of ongoing research.

Evidence Base for Symptomatic Management of Acute Oral and Pharyngeal Irritation

Studies for Acute Viral Pharyngitis (Sore Throat)

Short-term, randomized, placebo-controlled trials explored the product’s role in outcomes related to physical discomfort and examined outcomes related to how symptoms change over time in adult populations with acute viral pharyngitis. The primary metrics measured were patient-reported outcomes describing perceived discomfort, principally pain intensity assessed using standardized scales.

Research describes patterns observed in the studies that compared the combination product against a placebo, primarily focusing on measurements of patient-reported discomfort over the short, defined time intervals of the trial. Since the research is confined to research exploring short-term symptom changes, there is limited information for long-term outcomes such as recurrence rates.

Studies for Tonsillopharyngitis (Adjunctive Role)

Research on tonsillopharyngitis was evaluated in patients with a confirmed diagnosis, with studies exploring the product’s function as an add-on agent alongside standard systemic antibiotic therapy. Outcomes monitored included objective changes in outcomes linked to inflammatory or irritative states and subjective pain scores. Research explored whether the combination was associated with changes in clinical signs, and the studies monitored how patient-reported outcomes describing perceived discomfort changed in the observed populations.

Studies for Oral Mucositis (Symptomatic and Preventive Use)

High-level evidence, including systematic reviews, has examined the role of the Benzydamine single-agent component (not the combination product) in preventing and addressing oral mucositis linked to specific cancer radiation treatments. This research examined outcomes related to delaying the progression to severe mucositis and changes in patient-reported outcomes describing perceived discomfort. What remains uncertain is the application of this evidence to the combination product, as the cornerstone research focuses specifically on the single-agent Benzydamine rinse formulation.

What is Still Uncertain About the Research for Andorex

A transparent review highlights key gaps where certainty remains low:

Follow-up durations were limited: The current body of research focuses heavily on acute management, and long-term data tracking patients beyond the acute episode is minimal.
Comparative evidence is limited: There is limited information for direct head-to-head trials comparing the specific dual-action product against other single-agent topical agents.

Frequently Asked Questions (FAQ)

Common questions about Andorex (FAQ)

Q: Why do some people experience mild headaches when starting Andorex?

According to the official product information, headache is listed as a mild side effect that has been reported by some users. These effects are generally uncommon and transient. The official documentation describes what to do in case of severe symptoms.

Q: What is the purpose of the black box warning (if any) associated with Andorex?

Official regulatory documents classify the possibility of a severe, life-threatening allergic reaction, called anaphylaxis, as a rare but serious risk. This risk is primarily associated with the Chlorhexidine component. A severe allergic reaction is classified as a medical emergency requiring immediate supportive care.

Q: Is it common to feel drowsy or dizzy when using Andorex?

Dizziness and drowsiness are listed in official patient documents as mild side effects that have been reported by some users. These effects are usually uncommon when the medicine is used correctly for local oromucosal administration.

Q: What are the reported effects of Andorex on kidney or liver function?

The official eligibility profile advises special caution for people with known severe kidney or liver disorders. This is because the body processes and eliminates the Benzydamine component via these organs. Case reports concerning the accidental ingestion of very high doses of the Benzydamine component have sometimes described effects on these organs.

Q: Is Andorex generally considered a well-tolerated drug?

Studies and official information indicate that the product is generally considered well tolerated when used for acute conditions. Clinical research has reported no serious adverse events in the observed study populations.

Q: How quickly do people typically notice an effect from Andorex?

The Benzydamine component acts as a local pain reliever by rapidly blocking nerve impulses in the mouth and throat. While this action is quick, the time it takes for a person to notice symptom relief can vary. Pharmacokinetic studies show that the medication reaches its highest level in the bloodstream relatively quickly after local application.

Q: Does Andorex have a risk of causing dependency?

Regulatory literature has noted that the Benzydamine component, when used at extremely high doses (such as by swallowing a large number of tablets), is vulnerable to abuse. This is due to its stimulant effects on the central nervous system which may cause symptoms like hallucinations. However, the approved form of Andorex is an oromucosal rinse or spray, which is not intended to be swallowed.

Q: Is Andorex available in a generic version?

The active ingredients are Benzydamine Hydrochloride and Chlorhexidine Gluconate, both of which are long-established chemical compounds. These compounds are listed in regulatory databases and are often included as components of various branded and unbranded products internationally.

Q: Does Andorex need to be tapered off, or can I stop taking it suddenly?

Regulatory documents state that continuous, uninterrupted use of the product should not exceed seven days. Because the product is used for a short, defined period and is applied locally, official guidelines do not typically include instructions for tapering the dose.

Q: Where can I find the official patient information leaflet for Andorex?

The official Patient Information Leaflet (PIL) or equivalent Summary of Product Characteristics is included in the product packaging. This authoritative information is also typically available on the websites of the national drug regulatory agencies that approved the medicine, such as the FDA or EMA.

Q: How does Andorex affect blood pressure or heart rate?

Clinical study data for topical use has indicated no statistically significant changes in blood pressure or heart rate for most users. However, in cases of accidental ingestion of very large doses of the Benzydamine component, official reports have noted that changes in heart rate and blood pressure are sometimes observed.

Q: What should I know about driving or operating machinery while taking Andorex?

According to the official regulatory labeling, the medicine has a negligible influence on a user's ability to drive or operate heavy machinery. This finding reflects the product's function as a topical application with limited systemic absorption.

Q: Are there any religious or dietary restrictions mentioned for Andorex ingredients?

Official patient documents often contain warnings about specific inactive ingredients (excipients) used in the formulation. For example, some documents mention excipients like tartrazine, which may be relevant for individuals with known allergies or dietary restrictions.

Q: What are the official guidelines regarding using Andorex before surgery?

Official information indicates that the product is intended for use before and after certain surgical operations, such as those involving the tissues surrounding the teeth in dentistry. This reflects its function in managing local pain and microbial load during procedures.

Q: How long after stopping Andorex does the medicine stay in my system?

Pharmacokinetic data indicates that the Benzydamine component has an elimination half-life of approximately 13 hours. A half-life is the time it takes for the amount of medicine in the body to be reduced by half. The overall duration the medicine remains detectable in the system depends on several factors.

Q: What should I do if I accidentally take two doses of Andorex?

Since this product is for local use and must be expelled, accidental or intentional ingestion of large quantities is considered an overdose. Guidance for such cases notes that symptoms like agitation, visual disturbances, or hallucinations may appear. Guidance for such cases emphasizes the need for immediate supportive care.

Q: Is Andorex available without a prescription in other countries?

The legal classification of the medicine varies internationally based on the country's national drug authority. For example, in certain regions like the European Union, the Benzydamine component's regulatory status is listed as Over-The-Counter (OTC).

Q: What does the research say about Andorex's potential for misuse?

Regulatory literature has noted that the Benzydamine component is vulnerable to misuse when ingested at high doses. This potential is linked to its central nervous system stimulant effects, which can be associated with abuse of high-dose, non-approved tablet forms.

How should Andorex be stored and disposed of?

Storage and Disposal Requirements for Andorex

The storage and disposal of Andorex must strictly adhere to the conditions specified in official regulatory labeling.

Storage Conditions

Requirement	Specific Instruction
Temperature	Store at or below 25 C or 30 C, depending on the formulation. Do not freeze.
Protection	Keep in the original container or outer carton and protect from light.
Child Safety	Must be kept out of the sight and reach of children.

The product must not be used after the expiry date or for more than 6 months after the initial opening of the bottle.

Disposal

Do not dispose of unused or expired Andorex via wastewater or household waste. Official instructions require patients to ask their pharmacist for guidance on proper disposal according to local pharmaceutical waste regulations.

Andorex